WallStreetZenWallStreetZen

NASDAQ: ABUS
Arbutus Biopharma Corp Stock

$3.29+0.01 (+0.3%)
Updated May 24, 2024
ABUS Price
$3.29
Fair Value Price
-$2.61
Market Cap
$620.88M
52 Week Low
$1.69
52 Week High
$3.44
P/E
-7.48x
P/B
5.42x
P/S
34.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$12.99M
Earnings
-$74.39M
Gross Margin
100%
Operating Margin
-570.46%
Profit Margin
-572.8%
Debt to Equity
0.31
Operating Cash Flow
-$78M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ABUS Overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ABUS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ABUS ($3.29) is overvalued by 226.23% relative to our estimate of its Fair Value price of -$2.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ABUS ($3.29) is not significantly undervalued (226.23%) relative to our estimate of its Fair Value price of -$2.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ABUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ABUS due diligence checks available for Premium users.

Be the first to know about important ABUS news, forecast changes, insider trades & much more!

ABUS News

Valuation

ABUS fair value

Fair Value of ABUS stock based on Discounted Cash Flow (DCF)
Price
$3.29
Fair Value
-$2.61
Undervalued by
226.23%
ABUS ($3.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ABUS ($3.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ABUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ABUS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.48x
Industry
15.58x
Market
32.03x

ABUS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.42x
Industry
6.08x
ABUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ABUS's financial health

Profit margin

Revenue
$1.5M
Net Income
-$17.9M
Profit Margin
-1,166.8%
ABUS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$150.3M
Liabilities
$35.7M
Debt to equity
0.31
ABUS's short-term assets ($135.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABUS's short-term assets ($135.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ABUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.3M
Investing
$11.7M
Financing
$24.4M
ABUS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ABUS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ABUS$620.88M+0.30%-7.48x5.42x
PHAR$624.77M+2.87%-54.13x2.82x
ZYME$616.55M+0.11%-4.90x1.41x
PHAT$614.62M+1.94%-2.35x-4.14x
TSHA$605.94M+9.46%-6.61x11.25x

Arbutus Biopharma Stock FAQ

What is Arbutus Biopharma's quote symbol?

(NASDAQ: ABUS) Arbutus Biopharma trades on the NASDAQ under the ticker symbol ABUS. Arbutus Biopharma stock quotes can also be displayed as NASDAQ: ABUS.

If you're new to stock investing, here's how to buy Arbutus Biopharma stock.

What is the 52 week high and low for Arbutus Biopharma (NASDAQ: ABUS)?

(NASDAQ: ABUS) Arbutus Biopharma's 52-week high was $3.44, and its 52-week low was $1.69. It is currently -4.36% from its 52-week high and 94.67% from its 52-week low.

How much is Arbutus Biopharma stock worth today?

(NASDAQ: ABUS) Arbutus Biopharma currently has 188,717,409 outstanding shares. With Arbutus Biopharma stock trading at $3.29 per share, the total value of Arbutus Biopharma stock (market capitalization) is $620.88M.

Arbutus Biopharma stock was originally listed at a price of $6.30 in Jul 26, 2007. If you had invested in Arbutus Biopharma stock at $6.30, your return over the last 16 years would have been -47.78%, for an annualized return of -3.98% (not including any dividends or dividend reinvestments).

How much is Arbutus Biopharma's stock price per share?

(NASDAQ: ABUS) Arbutus Biopharma stock price per share is $3.29 today (as of May 24, 2024).

What is Arbutus Biopharma's Market Cap?

(NASDAQ: ABUS) Arbutus Biopharma's market cap is $620.88M, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arbutus Biopharma's market cap is calculated by multiplying ABUS's current stock price of $3.29 by ABUS's total outstanding shares of 188,717,409.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.